Suppr超能文献

用于整合素α(v)β(3)表达的微型正电子发射断层显像(microPET)成像的(68)镓标记多聚体RGD肽

(68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression.

作者信息

Li Zi-Bo, Chen Kai, Chen Xiaoyuan

机构信息

Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305-5484, USA.

出版信息

Eur J Nucl Med Mol Imaging. 2008 Jun;35(6):1100-8. doi: 10.1007/s00259-007-0692-y. Epub 2008 Jan 19.

Abstract

PURPOSE

We and others have reported that (18)F- and (64)Cu-labeled arginine-glycine-aspartate (RGD) peptides allow positron emission tomography (PET) quantification of integrin alpha(v)beta(3) expression in vivo. However, clinical translation of these radiotracers is partially hindered by the necessity of cyclotron facility to produce the PET isotopes. Generator-based PET isotope (68)Ga, with a half-life of 68 min and 89% positron emission, deserves special attention because of its independence of an onsite cyclotron. The goal of this study was to investigate the feasibility of (68)Ga-labeled RGD peptides for tumor imaging.

METHODS

Three cyclic RGD peptides, c(RGDyK) (RGD1), Ec(RGDyK) (RGD2), and E{Ec(RGDyK)}(2) (RGD4), were conjugated with macrocyclic chelator 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) and labeled with (68)Ga. Integrin affinity and specificity of the peptide conjugates were assessed by cell-based receptor binding assay, and the tumor targeting efficacy of (68)Ga-labeled RGD peptides was evaluated in a subcutaneous U87MG glioblastoma xenograft model.

RESULTS

U87MG cell-based receptor binding assay using (125)I-echistatin as radioligand showed that integrin affinity followed the order of NOTA-RGD4 > NOTA-RGD2 > NOTA-RGD1. All three NOTA conjugates allowed nearly quantitative (68)Ga-labeling within 10 min (12-17 MBq/nmol). Quantitative microPET imaging studies showed that (68)Ga-NOTA-RGD4 had the highest tumor uptake but also prominent activity accumulation in the kidneys. (68)Ga-NOTA-RGD2 had higher tumor uptake (e.g., 2.8 +/- 0.1%ID/g at 1 h postinjection) and similar pharmacokinetics (4.4 +/- 0.4 tumor/muscle ratio, 2.0 +/- 0.1 tumor/liver ratio, and 1.1 +/- 0.1 tumor/kidney ratio) compared with (68)Ga-NOTA-RGD1.

CONCLUSIONS

The dimeric RGD peptide tracer (68)Ga-NOTA-RGD2 with good tumor uptake and favorable pharmacokinetics warrants further investigation for potential clinical translation to image integrin alpha(v)beta(3).

摘要

目的

我们和其他研究人员已报道,(18)F和(64)Cu标记的精氨酸 - 甘氨酸 - 天冬氨酸(RGD)肽可通过正电子发射断层扫描(PET)对体内整合素α(v)β(3)表达进行定量分析。然而,这些放射性示踪剂的临床应用部分受到回旋加速器设施生产PET同位素必要性的阻碍。基于发生器的PET同位素(68)Ga半衰期为68分钟,正电子发射率为89%,因其无需现场回旋加速器而值得特别关注。本研究的目的是探讨(68)Ga标记的RGD肽用于肿瘤成像的可行性。

方法

将三种环状RGD肽,c(RGDyK)(RGD1)、E[c(RGDyK)](2)(RGD2)和E{E[c(RGDyK)](2)}(2)(RGD4)与大环螯合剂1,4,7 - 三氮杂环壬烷 - 1,4,7 - 三乙酸(NOTA)偶联,并用(68)Ga标记。通过基于细胞的受体结合试验评估肽偶联物的整合素亲和力和特异性,并在皮下U87MG胶质母细胞瘤异种移植模型中评估(68)Ga标记的RGD肽的肿瘤靶向效果。

结果

以(125)I - 蛇毒素作为放射性配体的基于U87MG细胞的受体结合试验表明,整合素亲和力顺序为NOTA - RGD4 > NOTA - RGD2 > NOTA - RGD1。所有三种NOTA偶联物在10分钟内均可实现近乎定量的(68)Ga标记(12 - 17 MBq/nmol)。定量microPET成像研究表明,(68)Ga - NOTA - RGD4的肿瘤摄取最高,但肾脏中也有明显的活性积聚。与(68)Ga - NOTA - RGD1相比,(68)Ga - NOTA - RGD2具有更高的肿瘤摄取(例如,注射后1小时为2.8±0.1%ID/g)和相似的药代动力学(肿瘤/肌肉比为4.4±0.4,肿瘤/肝脏比为2.0±0.1,肿瘤/肾脏比为1.1±0.1)。

结论

具有良好肿瘤摄取和有利药代动力学的二聚体RGD肽示踪剂(68)Ga - NOTA - RGD2值得进一步研究,以探讨其在整合素α(v)β(3)成像方面潜在的临床应用价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验